Zobrazeno 1 - 10
of 29
pro vyhledávání: '"MESH : Clinical Trials, Phase II as Topic"'
Autor:
Magnani, A., Semeraro, M., Adam, F., Booth, C., Dupré, L., Morris, E. C., Gabrion, A., Roudaut, C., Borgel, D., Toubert, A., Clave, E., Abdo, C., Gorochov, G., Petermann, R., Guiot, M., Miyara, M., Moshous, D., Magrin, E., Denis, A., Suarez, F., Lagresle, C., Roche, A. M., Everett, J., Trinquand, A., Guisset, M., Bayford, J. Xu, Hacein-Bey-Abina, S., Kauskot, A., Elfeky, R., Rivat, C., Abbas, S., Gaspar, H. B., Macintyre, E., Picard, C., Bushman, F. D., Galy, A., Fischer, A., Six, E., Thrasher, A. J., Cavazzana, M.
Publikováno v:
NATURE MEDICINE
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Universidad de las Islas Baleares
Nature Medicine
Nature Medicine, 2022, 28 (1), pp.71-80. ⟨10.1038/s41591-021-01641-x⟩
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Universidad de las Islas Baleares
Nature Medicine
Nature Medicine, 2022, 28 (1), pp.71-80. ⟨10.1038/s41591-021-01641-x⟩
Patients with Wiskott–Aldrich syndrome (WAS) lacking a human leukocyte antigen-matched donor may benefit from gene therapy through the provision of gene-corrected, autologous hematopoietic stem/progenitor cells. Here, we present comprehensive, long
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f3f98b89d4b68a773ab2a2e9643726a
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=21058
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=21058
Autor:
Thierry, Alain, Pastor, Brice, Pisareva, Ekaterina, Ghiringhelli, Francois, Bouché, Olivier, de La Fouchardière, Christelle, Vanbockstael, Julie, Smith, Denis, François, Eric, dos Santos, Mélanie, Botsen, Damien, Ellis, Stephen, Fonck, Marianne, André, Thierry, Guardiola, Emmanuel, Khemissa, Faiza, Linot, Benjamin, Martin-Babau, J., Rinaldi, yves, Assenat, Eric, Clavel, Lea, Dominguez, Sophie, Gavoille, Celine, Sefrioui, David, Pezzella, Veronica, Mollevi, Caroline, ychou, Marc, Mazard, Thibault
Publikováno v:
JAMA Network Open
JAMA Network Open, American Medical Association, 2021, 4 (9), pp.e2124483. ⟨10.1001/jamanetworkopen.2021.24483⟩
JAMA Network Open, American Medical Association, 2021, 4 (9), pp.e2124483. ⟨10.1001/jamanetworkopen.2021.24483⟩
This cohort study assesses the association of local and national COVID-19 restrictions with tumor burden, as measured by total plasma circulating tumor DNA concentration, among patients newly diagnosed with metastatic colorectal cancer.
Key Poin
Key Poin
Autor:
François Quenet, Christian Sengel, Lauranne Piron, Anthony Dohan, Patrick Chevallier, Emilie Lermite, Chloé Guillot, Boris Guiu, Laurent Vervueren, Agnès Rode, Antoine Bouvier, Jean-Baptiste Pinaquy, Christophe Laurent, Emmanuel Deshayes, Bruno Lapuyade
Publikováno v:
BMC Cancer
BMC Cancer, BioMed Central, 2020, 20 (1), pp.574. ⟨10.1186/s12885-020-07065-z⟩
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
BMC Cancer, BioMed Central, 2020, 20 (1), pp.574. ⟨10.1186/s12885-020-07065-z⟩
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Background In patients undergoing major liver resection, portal vein embolization (PVE) has been widely used to induce hypertrophy of the non-embolized liver in order to prevent post-hepatectomy liver failure. PVE is a safe and effective procedure, b
Autor:
Letestu, Rémi, Dahmani, Abdelmalek, Boubaya, Marouane, Baseggio, Lucile, Campos, Lydia, Chatelain, Bernard, Debliquis, Agathe, Drénou, Bernard, Jacob, Marie-Christine, Legac, Eric, Le Garff-Tavernier, Magali, Lhoumeau, Anne-Catherine, Quiney, Claire, Robillard, Nelly, Ticchioni, Michel, Aanei, Carmen, Katsahian, Sandrine, Delepine, Roselyne, Vaudaux, Sandrine, Rouillé, Valérie, Béné, Marie-Christine, Dartigeas, Caroline, Van Den Neste, Eric, Leprêtre, Stéphane, Feugier, Pierre, Cartron, Guillaume, Leblond, Véronique, Lévy, Vincent, Cymbalista, Florence, Cailleres, Sylvie, Damaj, Gandhi, Royer, Bruno, Gardembas, Martine, Dib, Mamoun, Truchan-Graczyk, Matgorzata, Hunault, Mathilde, Foussard, Charles, Corront, Bernadette, Parry, Anne, Orsini-Piocelle, Frédérique, Trouillier, Sébastien, Slama, Bohiane, Lepeu, Gérard, Zerazhi, Hacene, Boulat, Olivier, Azzedine, Ahmed, Araujo, Carla, Banos, Anne, Bauduer, Frédéric, Dutel, Jean-Luc, Ghomari, Kamel, Deconinck, Eric, Brion, Annie, Vuillier, Jacqueline, Saad, Alain, El Yamani, Abderrazak, Rodon, Philippe, Soubeyran, Pierre, Etienne, Gabriel, Dilhuydy, Marie-Sarah, Bouabdallah, Krimo, Leguay, Thibaut, Chouffi, Bachra, Pollet, Bertrand, Maakaroun, Abdallah, Guillerm, Gaëlle, Berthou, Christian, Cheron, Nathalie, ANDRÉ, Marc, Vilque, Jean Pierre, Fruchart, Christophe, Voillat, Laurent, Pica, Gian Matteo, Corm, Sélim, Micléa, Jean-Michel, Souleau, Bertrand, Molucon-Chabrot, Cécile, De Renzis, Benoit, Tournilhac, Olivier, Bay, Jacques-Olivier, Chaleteix, Carine, Guieze, Romain, Fleury, Joel, Precupanu, Cristina, Bouledroua, Selwa, Haiat, Stéphanie, Petitdidier, Charlotte, Dupuis, Jehan, Belhadj, Karim, Casasnovas, Olivier, Bastie, Jean-Noel, Ferrant, Emmanuelle, Gholam, Dany, Molina, Lysiane, Garban, Frédéric, Tiab, Mourad, Maisonneuve, Hervé, Villemagne, Bruno, Jacomy, Dominique, Besson, Caroline, Tertian, Gérard, Laribi, Kamel, Morel, Pierre, Cazin, Bruno, Moreau, Stéphane, Reminieras, Liliane, Rapp, Marie-José, Moreau, Philippe, Sebban, Catherine, Michallet, Anne-Sophie, Salles, Gilles, Broussais, Florence, Aurran-Schleinitz, Thérèse, Coso, Diane, Abarah, Wajed, Kulekci, Claire, Dorvaux, Véronique, Carassou, Philippe, Guibaud, Isabelle, Christian, Bernard, Graux, Carlos, Rossi, Jean-François, Quittet, Philippe, Dubois, Alain, Eisenmann, Jean-Claude, Morineau, Nadine, Mahé, Béatrice, Karsenti, Jean-Michel, Jourdan, Eric, Legouffe, Eric, Alexis-Vigier, Magda, Boulet, Jean-Michel, Aoudjhane, Malek, Thiéblemont, Catherine, Andreoli, Anna Lisa, Dreyfus, François, Choquet, Sylvain, Maloum, Karim, Merle-Béral, Hélène, Vekhoff, Anne, Decaudin, Didier, Brault, Philippe, Delarue, Richard, Janvier, Maud, Soussain, Carole, Vallantin, Xavier, Sanhes, Laurence, Dreyfus, Brigitte, Tomowiak, Cécile, Benramdane, Riad, Gonzalez, Hugo, Blaise-Brenna, Anne, Kolb, Brigitte, Delmer, Alain, Dauriac, Charles, Houot, Roch, Escoffre-Barbe, Martine, Lamy, Thierry, De Guibert, Sophie, Bernard, Marc, Grosbois, Bernard, Brehar, Oana, Morice, Patrick, Guyotat, Denis, Jaubert, Jérome, Portois, Christelle, Fornecker, Luc-Matthieu, Herbrecht, Raoul, Bilger, Karin, Ame, Shanti, Ysebaert, Loic, Godmer, Pascal, Jardel, Henry
Publikováno v:
Leukemia
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (6), pp.1597-1609. ⟨10.1038/s41375-020-01009-z⟩
Leukemia, Vol. 35, no. 6, p. 1597-1609 (2020)
Leukemia, Nature Publishing Group: Open Access Hybrid Model Option B, 2021, 35 (6), pp.1597-1609. ⟨10.1038/s41375-020-01009-z⟩
Leukemia, Vol. 35, no. 6, p. 1597-1609 (2020)
International audience; Measurable residual disease (MRD) status is widely adopted in clinical trials in patients with chronic lymphocytic leukemia (CLL). Findings from FILO group trials (CLL2007FMP, CLL2007SA, CLL2010FMP) enabled investigation of th
Autor:
Felice Giangaspero, Chris Jones, Christophe Deroulers, Dominique Figarella-Branger, Marie-Cécile Le Deley, Thomas S. Jacques, Gwénaël Le Teuff, Tim Jaspan, Torsten Pietsch, J. Grill, Pascale Varlet, Felipe Andreiuolo, Christine Haberler
Publikováno v:
Neuro-Oncology
Neuro-Oncology, 2020, 22 (1), pp.116-127. ⟨10.1093/neuonc/noz142⟩
Neuro-Oncology, 2019, 22 (1), pp.116-127. ⟨10.1093/neuonc/noz142⟩
Neuro-Oncology, Oxford University Press (OUP), 2020, 22 (1), pp.116-127. ⟨10.1093/neuonc/noz142⟩
Neuro-Oncology, 2020, 22 (1), pp.116-127. ⟨10.1093/neuonc/noz142⟩
Neuro-Oncology, 2019, 22 (1), pp.116-127. ⟨10.1093/neuonc/noz142⟩
Neuro-Oncology, Oxford University Press (OUP), 2020, 22 (1), pp.116-127. ⟨10.1093/neuonc/noz142⟩
Background The World Health Organization (WHO) adult glioma grading system is questionable in pediatric high-grade gliomas (pHGGs), which are biologically distinct from adult HGGs. We took advantage of the neuropathological review data obtained durin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c30c372eca73b2c55e143342be6cccbc
https://hal.science/hal-03141590
https://hal.science/hal-03141590
Autor:
Olivier Chinot, Robert L. Coleman, Herbert Hurwitz, Josep Garcia, David Miles, Alan Sandler, Regula Deurloo
Publikováno v:
Cancer Treatment Reviews
Cancer Treatment Reviews, WB Saunders, 2020, 86, pp.102017. ⟨10.1016/j.ctrv.2020.102017⟩
Cancer Treatment Reviews, 2020, 86, pp.102017. ⟨10.1016/j.ctrv.2020.102017⟩
Cancer Treatment Reviews, WB Saunders, 2020, 86, pp.102017. ⟨10.1016/j.ctrv.2020.102017⟩
Cancer Treatment Reviews, 2020, 86, pp.102017. ⟨10.1016/j.ctrv.2020.102017⟩
International audience; When the VEGF-A-targeting monoclonal antibody bevacizumab (Avastin®) entered clinical practice more than 15 years ago, it was one of the first targeted therapies and the first approved angiogenesis inhibitor. Marking the begi
Autor:
Anna Durigova, Alice Cuenant, Krisztian Homicsko, Marie Vinches, Nadia Hayaoui, Marie Alexandre, Marie Viala, Luca Gianni, Diego Tosi, Céline Gongora, Caroline Mollevi
Publikováno v:
British Journal of Cancer
British Journal of Cancer, Cancer Research UK, 2018, 118 (5), pp.679-697. ⟨10.1038/bjc.2017.473⟩
British journal of cancer, vol. 118, no. 5, pp. 679-697
British Journal of Cancer, Cancer Research UK, 2018, 118 (5), pp.679-697. ⟨10.1038/bjc.2017.473⟩
British journal of cancer, vol. 118, no. 5, pp. 679-697
International audience; BACKGROUND: Our previous survey on first-in-human trials (FIHT) of monoclonal antibodies (mAbs) showed that, due to their limited toxicity, the recommended phase II dose (RP2D) was only tentatively defined.METHODS: We identifi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b03f0a204474d74cee7ad53b33df4109
https://hal.umontpellier.fr/hal-02292921
https://hal.umontpellier.fr/hal-02292921
Autor:
Giovanni L. Pappagallo, David Azria, Orazio Caffo, Maria De Santis, Enzo Galligioni, Ananya Choudhury, Borut Kragelj, Daniel A. Hamstra, Gianni Fellin, C. Thompson
Publikováno v:
Radiotherapy and Oncology
Radiotherapy and Oncology, Elsevier, 2016, 121 (2), pp.193-198. ⟨10.1016/j.radonc.2016.09.006⟩
Radiotherapy and Oncology, Elsevier, 2016, 121 (2), pp.193-198. ⟨10.1016/j.radonc.2016.09.006⟩
International audience; PURPOSE:Although radical cystectomy is still considered the standard of care for most localized muscle-invasive bladder cancer (MIBC) patients, bladder-sparing strategies with chemoradiotherapy have demonstrated comparable loc
Autor:
George D. Demetri, Andres Poveda, Federica Grosso, Jaap Verweij, Vicente Alfaro, Jean-Yves Blay, Patrick Schöffski, Antonio Nieto, Paolo G. Casali, Robert G. Maki, Axel Le Cesne, Pilar Lardelli, Carme Balaña, Sara Cresta
Publikováno v:
European Journal of Cancer
European Journal of Cancer, Elsevier, 2012, 48 (16), pp.3036-44. ⟨10.1016/j.ejca.2012.05.012⟩
European Journal of Cancer, 48(16), 3036-3044. Elsevier Ltd.
European Journal of Cancer, Elsevier, 2012, 48 (16), pp.3036-44. ⟨10.1016/j.ejca.2012.05.012⟩
European Journal of Cancer, 48(16), 3036-3044. Elsevier Ltd.
International audience; AIMS: Approximately 20% of soft tissue sarcomas (STS) have subtype-specific chromosomal translocations; these generate chimeric oncoproteins which can act as abnormal transcription factors. Since trabectedin can bind to DNA an
Publikováno v:
Cancer Journal
Cancer Journal, Lippincott, Williams & Wilkins, 2009, 15 (5), pp.361-5. ⟨10.1097/PPO.0b013e3181bd045f⟩
Cancer Journal, Lippincott, Williams & Wilkins, 2009, 15 (5), pp.361-5. ⟨10.1097/PPO.0b013e3181bd045f⟩
International audience; A main criterion to identify activity in phase II studies is the response rates achieved in a well-defined subset of patients. The response could be defined as a measure of tumor shrinkage. For 30 years, metric methods have be